Top Back to top

The role of measurable residual disease (MRD) at the time of allogeneic stem cell transplantation in patients with AML in CR transplanted from unrelated donors with Post transplant cyclophosphamide

Acute Leukemia Working Party (ALWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Acute Myeloid Leukaemia (AML)
Short title:
Primary objective:
This study is a retrospective registry-based analysis to study and role/prognostic impact of pre -alloSCT MRD in patients with AML in complete remission undergoing allogeneic transplantation from unrelated donor with post transplantation cyclophosphamide as GVHD prophylaxis.
Key inclusion criteria:
• de-novo AML
• adults, age ≥ 18 years
• Transplant dates 2010-2018
• HLA 10/10 matched unrelated donors (if we need more numbers we include 9/10)
• PBSC or bone-marrow as the stem cell source
• CR1 at the time of transplantation
• Myeloablative or Reduced- intensity conditioning
• Receiving PTCy as GVHD prophylaxis
• Available MRD tests prior to transplantation

Principal investigator:
Arnon Nagler